Paper40717023
Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting.
Hussain M and 2 others. FEBS J, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting. Papers, record 40717023. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40717023
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Posttranslational modifications of phosphodiesterase type 4 enzymes represent novel points for therapeutic targeting.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | Major topic |
| Protein Processing, Post-Translational | Major topic |
| Phosphodiesterase 4 Inhibitors | Major topic |
| Humans | |
| Cyclic AMP | |
| Animals | |
| Signal Transduction | |
| Molecular Targeted Therapy |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/y00364/1 | Medical Research Council | United Kingdom | PubMed | |
| SP/16/3/32317 | British Heart Foundation | United Kingdom | PubMed |
Source PubMed
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31388135 | Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/31388135 | PubMed |
| 2 | 15066910 | Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. | Br J Pharmacol | 2004 | https://conductscience.org/library/papers/15066910 | PubMed |
| 3 | 10022832 | The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. | EMBO J | 1999 | https://conductscience.org/library/papers/10022832 | PubMed |
| 4 | 15182229 | PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. | Biochem J | 2004 | https://conductscience.org/library/papers/15182229 | PubMed |
| 5 | 25680530 | The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. | FEBS Lett | 2015 | https://conductscience.org/library/papers/25680530 | PubMed |
| 6 | 20196770 | Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. | Biochem J | 2010 | https://conductscience.org/library/papers/20196770 | PubMed |
| 7 | 35091346 | A chemical method for genome- and proteome-wide enrichment and O-GlcNAcylation profiling of chromatin-associated proteins. | Talanta | 2022 | https://conductscience.org/library/papers/35091346 | PubMed |
| 8 | 22975349 | Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D. | Biochem Biophys Res Commun | 2012 | https://conductscience.org/library/papers/22975349 | PubMed |
| 9 | 24815749 | Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression. | Cell Signal | 2014 | https://conductscience.org/library/papers/24815749 | PubMed |
| 10 | 38797258 | Low PDE4A expression promoted the progression of ovarian cancer by inducing Snail nuclear translocation. | Exp Cell Res | 2024 | https://conductscience.org/library/papers/38797258 | PubMed |
| 11 | 23514139 | Decoding the SUMO signal. | Biochem Soc Trans | 2013 | https://conductscience.org/library/papers/23514139 | PubMed |
| 12 | 26192746 | The role of ventral striatal cAMP signaling in stress-induced behaviors. | Nat Neurosci | 2015 | https://conductscience.org/library/papers/26192746 | PubMed |
| 13 | 35042991 | PROTAC targeted protein degraders: the past is prologue. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/35042991 | PubMed |
| 14 | 10829034 | The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. | J Biol Chem | 2000 | https://conductscience.org/library/papers/10829034 | PubMed |
| 15 | 39673076 | Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera. | FEBS J | 2025 | https://conductscience.org/library/papers/39673076 | PubMed |
| 16 | 24555506 | The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s). | Biochem J | 2014 | https://conductscience.org/library/papers/24555506 | PubMed |
| 17 | 39851300 | Artificial Intelligence Transforming Post-Translational Modification Research. | Bioengineering (Basel) | 2024 | https://conductscience.org/library/papers/39851300 | PubMed |
| 18 | 35695071 | A cAMP signalosome in primary cilia drives gene expression and kidney cyst formation. | EMBO Rep | 2022 | https://conductscience.org/library/papers/35695071 | PubMed |
| 19 | 27908835 | Modulation of signaling through GPCR-cAMP-PKA pathways by PDE4 depends on stimulus intensity: Possible implications for the pathogenesis of acrodysostosis without hormone resistance. | Mol Cell Endocrinol | 2017 | https://conductscience.org/library/papers/27908835 | PubMed |
| 20 | 25831493 | Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/25831493 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41157273 | PDE4-Selective Inhibition in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Different Agents or Different Targets? | Life (Basel) | 2025 | https://conductscience.org/library/papers/41157273 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PDE4A | 5141 | PubTator's text mining | https://conductscience.org/library/genes/5141 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40717023
GET https://conductscience.org/api/papers/v1/40717023/references?page=2